Cancer
Nasopharyngeal carcinoma
鼻咽癌NPC
A cancer that starts in the lining of the nasopharynx. It is most common in Southeast Asian populations and is associated with Epstein–Barr virus infection.
Definition adapted from MeSH (US National Library of Medicine)
- hospitals in mainland China
- 183
- cities
- 69
with a paper from 2016–2025 or a registered study
where those hospitals are
Mainland China accounts for 76% of the world's English-language research papers on nasopharyngeal carcinoma, 2021–2025 (67% in 2016–2020), and 52% of the world's registered trials on it have a site in China.
Research activity in public records, not a rating of care and not medical advice. How the numbers are made
183 hospitals in 69 cities
Order: papers led on nasopharyngeal carcinoma, 2021–2025, then A–Z. Research activity, not a rating of care.
A hospital is listed when it led at least 3 papers or 1 trial on nasopharyngeal carcinoma, or was a site in 3 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions
Cities with the most listed hospitals
Each opens nasopharyngeal carcinoma in that city. 59 more cities are in the menu below.
- 483 papers led
- 87 papers led
- 63 papers ledNo open trial led
- 54 papers led
- 53 papers led
- 48 papers led
- 44 papers led
- 38 papers led
- 35 papers ledNo open trial led
- 33 papers led
- 33 papers led
- 32 papers led
- 29 papers led
- 27 papers led
- 26 papers led
- 25 papers led
- 25 papers ledNo open trial led
- 25 papers led
- 25 papers led
- 21 papers ledNo open trial led
- 20 papers led
- 19 papers ledNo open trial led
- 19 papers led
- 18 papers led
- 17 papers ledNo open trial led
- 16 papers ledNo open trial led
- 15 papers ledNo open trial led
- 15 papers ledNo open trial led
- 14 papers led
- 14 papers led
- 14 papers led
- 14 papers ledNo open trial led
- 14 papers led
- 14 papers led
- 14 papers ledNo open trial led
- 13 papers ledNo open trial led
- 13 papers ledNo open trial led
- 12 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 10 papers ledNo open trial led
- 9 papers ledNo open trial led
- 9 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers led
- 5 papers led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
No listed hospital matches these filters.
By university or health system 60
Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.
- 555 papers led6 hospitals
- 154 papers led5 hospitals
- 124 papers led6 hospitals
- 118 papers led6 hospitals
- 80 papers led6 hospitals
- 79 papers led6 hospitals
- 52 papers led6 hospitals
- 46 papers led3 hospitals
- 45 papers led5 hospitals
- 35 papers led1 hospital
- 33 papers led6 hospitals
- 31 papers led2 hospitals
- 29 papers led2 hospitals
- 27 papers led3 hospitals
- 24 papers led3 hospitals
- 24 papers led5 hospitals
- 22 papers led4 hospitals
- 22 papers led6 hospitals
- 22 papers led6 hospitals
- 21 papers led1 hospital
- 20 papers led1 hospital
- 19 papers led1 hospital
- 18 papers led6 hospitals
- 17 papers led2 hospitals
- 17 papers led3 hospitals
- 17 papers led6 hospitals
- 16 papers led5 hospitals
- 15 papers led1 hospital
- 13 papers led6 hospitals
- 13 papers led5 hospitals
- 12 papers led2 hospitals
- 12 papers led5 hospitals
- 11 papers led3 hospitals
- 11 papers led1 hospital
- 11 papers led5 hospitals
- 10 papers led3 hospitals
- 10 papers led2 hospitals
- 10 papers led2 hospitals
- 10 papers led4 hospitals
- 10 papers led3 hospitals
- 9 papers led2 hospitals
- 8 papers led1 hospital
- 8 papers led1 hospital
- 8 papers led1 hospital
- 8 papers led2 hospitals
- 7 papers led1 hospital
- 5 papers led2 hospitals
- 4 papers led2 hospitals
- 4 papers led1 hospital
- 4 papers led2 hospitals
- 3 papers led1 hospital
- 3 papers led3 hospitals
- 3 papers led2 hospitals
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led1 hospital
- 1 paper led1 hospital
open trials on nasopharyngeal carcinoma in China
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 8 Nov 2026, with at least one listed hospital as lead sponsor or site. 143 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.
Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial
What the phases mean (US National Cancer Institute)
- RecruitingEnvafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
- Phase
- Phase 2
- Started
- 2026-02
- Registry
- NCT06059261
Age 18 years to 65 years (registered criteria)
Led by Chongqing University Cancer HospitalChongqing
- RecruitingHypofractionated Radiotherapy for Nasopharyngeal Carcinoma
- Phase
- N/A
- Started
- 2026-02
- Registry
- NCT06796270
Age 18 years to 75 years (registered criteria)
Led by Hainan General Hospital / Hainan Medical University hospitalsHaikou
- RecruitingInternational Collaborative Study on AJCC/UICC TNM-10 for Nasopharyngeal Cancer
- Phase
- Not given
- Started
- 2026-01
- Registry
- NCT07013461
Age 18 years to Not stated (registered criteria)
Led by The University of Hong Kong–Shenzhen HospitalShenzhen
- RecruitingPD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07235319
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 4 listed hospitals as study sitesChangsha, Fuzhou, Guangzhou, Hangzhou, Nanning
- RecruitingLDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07325539
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteGuangzhou, Shenzhen
- RecruitingMRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC
- Phase
- Phase 2
- Started
- 2026-06
- Registry
- NCT07331428
Age 18 years to 70 years (registered criteria)
Led by Fujian Cancer HospitalFuzhou
- RecruitingPD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC
- Phase
- Phase 2
- Started
- 2026-02
- Registry
- NCT07332247
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingToripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2026-03
- Registry
- NCT07362979
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 3 listed hospitals as study sitesDongguan, Guangzhou, Shenzhen, Zhanjiang
- RecruitingIMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features
- Phase
- Not given
- Started
- 2026-01
- Registry
- NCT07376603
Age 18 years to 70 years (registered criteria)
Led by Fujian Cancer HospitalFuzhou
- RecruitingA Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2026-02
- Registry
- NCT07392320
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingBecotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
- Phase
- Phase 3
- Started
- 2026-03
- Registry
- NCT07459296
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Guangxi Medical UniversityNanning
- RecruitingBecotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy
- Phase
- Phase 2
- Started
- 2026-02
- Registry
- NCT07496190
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingMaintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07528183
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 3 listed hospitals as study sitesFuzhou, Guangzhou, Nanning, Wuhan
- RecruitingTopical Chlorhexidine Spray for the Prevention of Acute Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma:
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07559877
Age 18 years to 75 years (registered criteria)
Led by Jiangxi Cancer HospitalNanchang
- RecruitingTaurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2026-05
- Registry
- NCT07567742
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingPhase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2026-05
- Registry
- NCT07584499
Age 2 years to 18 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingIntratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors
- Phase
- Phase 1
- Started
- 2026-03
- Registry
- NCT07625423
Age 18 years to 65 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingIndividualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2026-07
- Registry
- NCT07661771
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 6 listed hospitals as study sitesChangsha, Dongguan, Foshan, Guangzhou, Shenzhen, Zhongshan
- RecruitingEfficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2026-07
- Registry
- NCT07705243
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingEfficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2026-07
- Registry
- NCT07706985
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingBecotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07781358
Age 18 years to 80 years (registered criteria)
Led by Eye & ENT Hospital of Fudan UniversityShanghai
- RecruitingProphylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07796789
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 2 listed hospitals as study sitesChangsha, Fuzhou, Guangzhou
- RecruitingDynamic Risk Prediction of Severe Myelosuppression in Nasopharyngeal Carcinoma
- Phase
- Not given
- Started
- 2026-08
- Registry
- NCT07819656
Age 18 years to Not stated (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingCTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2025-01
- Registry
- NCT06095154
Age 18 years to 70 years (registered criteria)
Led by Fujian Cancer HospitalFuzhou
- RecruitingQL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
- Phase
- Phase 3
- Started
- 2025-05
- Registry
- NCT06749899
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 17 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xiamen, Zhongshan
- RecruitingProphylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC
- Phase
- Phase 3
- Started
- 2025-01
- Registry
- NCT06752239
Age 18 years to 70 years (registered criteria)
Led by Jiangxi Cancer HospitalNanchang
- RecruitingLDRT and Chemoimmunotherapy in NPC With Liver Metastasis
- Phase
- Phase 2
- Started
- 2025-01
- Registry
- NCT06788002
Age 18 years to 70 years (registered criteria)
Led by Hunan Cancer Hospital; 2 listed hospitals as study sitesChangsha
- RecruitingEGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Registry
- NCT06802835
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingTwo-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC
- Phase
- Phase 2
- Started
- 2025-02
- Registry
- NCT06811844
Age 18 years to 65 years (registered criteria)
Led by First Affiliated Hospital of Xiamen University; 1 listed hospital as study siteHaikou, Xiamen
- RecruitingDevelopment and Validation of a Deep Learning Model to Predict Distant Metastases in Nasopharyngeal Carcinoma Using Whole Slide Imaging and MRI
- Phase
- Not given
- Started
- 2025-02
- Registry
- NCT06831357
Age not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT06839066
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Fuzhou, Ganzhou, Guangzhou, Hangzhou, Nanning, Shenzhen, Wuhan, Zhongshan
- RecruitingGAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.
- Phase
- Phase 2
- Started
- 2025-01
- Registry
- NCT06851247
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingComparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas
- Phase
- N/A
- Started
- 2025-01
- Registry
- NCT06870435
Age 30 years to 69 years (registered criteria)
Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai
- RecruitingReduced Dose Radiotherapy vs Standard Dose Radiotherapy for Early Stage Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2025-05
- Registry
- NCT06912698
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingTN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2025-05
- Registry
- NCT06912711
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2025-05
- Registry
- NCT06976190
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingPhase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2025-05
- Registry
- NCT07000643
Age 18 years to 75 years (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- RecruitingA Randomized Controlled Trial of Spermidine for the Prevention of Radiation-Induced Xerostomia in Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)
- Phase
- Phase 1/Phase 2
- Started
- 2025-06
- Registry
- NCT07035626
Age 18 years to 80 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingCombination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT07070479
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChangsha, Guangzhou, Zhongshan, Zhuhai
- RecruitingIparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07085234
Age 18 years to 65 years (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingEffect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2025-01
- Registry
- NCT07085988
Age 18 years to Not stated (registered criteria)
Led by Jiangxi Cancer HospitalNanchang
- RecruitingIparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial
- Phase
- Phase 2
- Started
- 2025-10
- Registry
- NCT07101744
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingToripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07136519
Age 18 years to 65 years (registered criteria)
Led by Affiliated Hospital of Guangdong Medical UniversityZhanjiang
- RecruitingPrecise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinoma
- Phase
- Not given
- Started
- 2025-08
- Registry
- NCT07137052
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingAdaptive Immunotherapy for Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2025-11
- Registry
- NCT07154069
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingSerplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2025-09
- Registry
- NCT07177443
Age 18 years to 65 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingPhase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer
- Phase
- Phase 3
- Started
- 2025-08
- Registry
- NCT07188584
Age 18 years to 70 years (registered criteria)
Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai
- RecruitingA Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
- Phase
- Phase 1/Phase 2
- Started
- 2025-11
- Registry
- NCT07258979
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Jiangmen, Kunming, Nanchang, Nanning, Shanghai, Shaoguan, Xiamen
- RecruitingInduction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II)
- Phase
- Phase 2
- Started
- 2025-10
- Registry
- NCT07277764
Age 18 years to 75 years (registered criteria)
Led by Jiangxi Cancer HospitalNanchang
- RecruitingIndividualized Neck Cervical Irradiation Prophylaxis Trial of NPC
- Phase
- Phase 3
- Started
- 2025-09
- Registry
- NCT07303023
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChengdu, Chongqing, Hangzhou, Shanghai
- RecruitingPrevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07311772
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Kunming, Nanning, Shanghai, Shantou, Wuzhou, Zhuhai
- RecruitingReduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
- Phase
- Phase 3
- Started
- 2025-11
- Registry
- NCT07328841
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesChangsha, Guangzhou, Nanning, Shantou, Wuhan, Wuzhou, Zhongshan, Zhuhai
- Recruiting40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2025-11
- Registry
- NCT07328854
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Kunming, Nanning, Shantou, Wuzhou, Zhongshan, Zhuhai
- RecruitingProton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07340515
Age 18 years to 70 years (registered criteria)
Led by Shandong Cancer Hospital and InstituteJinan
- RecruitingSintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07581821
Age 18 years to 65 years (registered criteria)
Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai
- RecruitingIC Plus Low-dose Radiation Plus Cadonilimab in LANPC
- Phase
- Phase 3
- Started
- 2024-01
- Registry
- NCT05941741
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 2 listed hospitals as study sitesGuangzhou, Nanchang, Nanning
- RecruitingA Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
- Phase
- Phase 2
- Started
- 2024-01
- Registry
- NCT05956587
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChongqing, Fuzhou, Guangzhou, Hangzhou, Linyi, Liuzhou, Nanchang, Tianjin, Wuhan, Xi'an, Zhengzhou
- RecruitingThe Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC
- Phase
- Not given
- Started
- 2024-01
- Registry
- NCT06182657
Age 18 years to Not stated (registered criteria)
Led by Jiangxi Cancer HospitalNanchang
- RecruitingClinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-09
- Registry
- NCT06194656
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingInvestigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC
- Phase
- Not given
- Started
- 2024-07
- Registry
- NCT06197776
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingAdjuvant vs Surgery Only in Early-stage Recurrent NPC
- Phase
- Phase 3
- Started
- 2024-06
- Registry
- NCT06228079
Age 18 years to 75 years (registered criteria)
Led by Eye & ENT Hospital of Fudan University; 6 listed hospitals as study sitesFuzhou, Nanning, Shanghai, Shenzhen
- RecruitingNeoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
- Phase
- Phase 3
- Started
- 2024-07
- Registry
- NCT06235203
Age 18 years to 75 years (registered criteria)
Led by Eye & ENT Hospital of Fudan University; 6 listed hospitals as study sitesFuzhou, Nanning, Shanghai, Shenzhen
- RecruitingReduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
- Phase
- Phase 3
- Started
- 2024-03
- Registry
- NCT06239727
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 21 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Haikou, Hangzhou, Nanchang, Nanjing, Nanning, Shantou, Tianjin, Wuhan, Xi'an, Xiamen, Zhanjiang
- RecruitingA Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
- Phase
- Phase 2/Phase 3
- Started
- 2024-02
- Registry
- NCT06241599
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingIndividualized Elective Neck Irradiation in NPC Patients
- Phase
- Phase 3
- Started
- 2024-04
- Registry
- NCT06241612
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingMaintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2024-03
- Registry
- NCT06277050
Age 18 years to 70 years (registered criteria)
Led by Jiangxi Cancer Hospital; 2 listed hospitals as study sitesGanzhou, Nanchang
- RecruitingA Mucosal Contouring Method Based on Swallowing-induced Breakthrough Pain for Radiation-induced Oropharyngeal Mucositis
- Phase
- Not given
- Started
- 2024-03
- Registry
- NCT06287788
Age 18 years to Not stated (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingTPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2024-03
- Registry
- NCT06301165
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesDongguan, Foshan, Guangzhou, Shenzhen, Wuhan
- RecruitingPlasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis
- Phase
- Not given
- Started
- 2024-02
- Registry
- NCT06307314
Age 18 years to Not stated (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingA Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis
- Phase
- Not given
- Started
- 2024-04
- Registry
- NCT06308328
Age 18 years to Not stated (registered criteria)
Led by Nanfang Hospital; 9 listed hospitals as study sitesChengdu, Guangzhou, Shanghai, Shaoguan, Shenzhen, Zhuhai
- RecruitingDe-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyngeal Carcinoma
- Phase
- N/A
- Started
- 2024-03
- Registry
- NCT06313450
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingSequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma
- Phase
- Not given
- Started
- 2024-01
- Registry
- NCT06321939
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer HospitalChangsha
- RecruitingSBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06323239
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingAdebrelimab and Chemoradiotherapy in High-risk LANPC
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06349889
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 3 listed hospitals as study sitesChengdu, Guangzhou, Xiamen
- RecruitingPretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients
- Phase
- N/A
- Started
- 2024-08
- Registry
- NCT06389201
Age 20 years to 70 years (registered criteria)
Led by Affiliated Hospital of Nantong UniversityNantong
- RecruitingA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06437522
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingEfficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial
- Phase
- Phase 3
- Started
- 2024-05
- Registry
- NCT06438627
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingDiagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma
- Phase
- Not given
- Started
- 2024-05
- Registry
- NCT06445088
Age not stated (registered criteria)
Led by Sun Yat-sen University Cancer Center; 4 listed hospitals as study sitesFuzhou, Guangzhou, Nanning, Wuzhou, Zhongshan
- RecruitingGP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06455410
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen Memorial Hospital; 7 listed hospitals as study sitesFoshan, Guangzhou, Liuzhou, Nanning, Shantou, Shenzhen
- RecruitingDeep Learning-based sbORN Diagnostic Model
- Phase
- Not given
- Started
- 2024-07
- Registry
- NCT06463392
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingClinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06472713
Age 18 years to 70 years (registered criteria)
Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai
- RecruitingA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06475300
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingNimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2024-08
- Registry
- NCT06509009
Age 18 years to 75 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingOnline Adaptive Radiotherapy for Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2024-05
- Registry
- NCT06516133
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingEndoscopic Surgery vs. Intensity Modulated Radiotherapy for Stage I Nasopharyngeal Carcinoma.
- Phase
- N/A
- Started
- 2024-03
- Registry
- NCT06533267
Age 18 years to 75 years (registered criteria)
Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai
- RecruitingConcurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma
- Phase
- Phase 1
- Started
- 2024-08
- Registry
- NCT06611150
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingUnder Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.
- Phase
- Phase 3
- Started
- 2024-07
- Registry
- NCT06675214
Age 18 years to 65 years (registered criteria)
Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai
- RecruitingSBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06676722
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- Recruiting"Xijiang Project" Screening Cohort for NPC
- Phase
- Not given
- Started
- 2024-11
- Registry
- NCT06787456
Age 30 years to 69 years (registered criteria)
Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai
- RecruitingA Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma(NPC)
- Phase
- Not given
- Started
- 2024-11
- Registry
- NCT06829147
Age not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingTrop2-targeted immunoPET Imaging of Solid Tumors
- Phase
- Phase 2/Phase 3
- Started
- 2024-12
- Registry
- NCT06851663
Age 18 years to 75 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingCD70-targeted immunoPET Imaging of Malignant Cancers
- Phase
- Phase 2
- Started
- 2024-12
- Registry
- NCT06852638
Age 18 years to 80 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingGemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
- Phase
- Phase 3
- Started
- 2023-05
- Registry
- NCT05854849
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingTwo Cycles VS Three Cycles Induction Chemotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2023-05
- Registry
- NCT05860868
Age 18 years to 65 years (registered criteria)
Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingReduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2023-05
- Registry
- NCT05877872
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingScreening Effect of Dual-energy CT Combined With Nasopharyngeal Endoscopy for Screening Nasopharyngeal Carcinoma
- Phase
- Not given
- Started
- 2023-02
- Registry
- NCT05884983
Age 30 years to 69 years (registered criteria)
Led by Zhongshan City People's HospitalZhongshan
- RecruitingEffect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
- Phase
- N/A
- Started
- 2023-06
- Registry
- NCT05892354
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Guangxi Medical University; 13 listed hospitals as study sitesFuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Liuzhou, Nanchang, Nanning, Wuzhou
- RecruitingReducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma
- Phase
- N/A
- Started
- 2023-08
- Registry
- NCT05994170
Age 18 years to 70 years (registered criteria)
Led by Zhongshan City People's HospitalZhongshan
- RecruitingDoxepin Solution for Alleviation of Stubborn Breakthrough Pain Induced by Swallowing in Patients Receiving Radiotherapy for Nasopharyngeal Carcinoma
- Phase
- N/A
- Started
- 2023-10
- Registry
- NCT06017895
Age 18 years to Not stated (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingGNT Induction Treatment in Locally Advanced NPC
- Phase
- Phase 3
- Started
- 2023-09
- Registry
- NCT06026878
Age 18 years to 75 years (registered criteria)
Led by Xijing HospitalXi'an
- RecruitingReduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy
- Phase
- Phase 3
- Started
- 2023-10
- Registry
- NCT06092957
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingTislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC
- Phase
- Phase 3
- Started
- 2023-12
- Registry
- NCT06177301
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingXerostomia-optimised IMRT Versus Standard IMRT in NPC
- Phase
- N/A
- Started
- 2023-10
- Registry
- NCT06282497
Age 18 years to 70 years (registered criteria)
Led by Zhongshan City People's HospitalZhongshan
- RecruitingSurgery Alone Verus Sugery Combined with Dose-reduced Radiotherapy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma
- Phase
- N/A
- Started
- 2023-11
- Registry
- NCT06688760
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Zhuhai
- RecruitingMetastatic Nasopharyngeal Carcinoma
- Phase
- Phase 1
- Started
- 2023-07
- Registry
- NCT06886347
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- Recruiting18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2022-01
- Registry
- NCT04813705
Age 18 years to 80 years (registered criteria)
Led by Taizhou HospitalTaizhou
- RecruitingToripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2022-03
- Registry
- NCT05147844
Age 18 years to 75 years (registered criteria)
Led by Xinqiao Hospital, Army Medical UniversityChongqing
- RecruitingChemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
- Phase
- Phase 3
- Started
- 2022-04
- Registry
- NCT05340491
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 10 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanning, Shanghai, Wuhan, Xi'an, Xiamen
- RecruitingMetronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2022-04
- Registry
- NCT05342792
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingSurgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma
- Phase
- N/A
- Started
- 2022-06
- Registry
- NCT05352321
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteGuangzhou
- RecruitingEnvafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.
- Phase
- Phase 2
- Started
- 2022-06
- Registry
- NCT05397769
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingEpstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening
- Phase
- Not given
- Started
- 2022-07
- Registry
- NCT05447169
Age 30 years to 62 years; men only (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingNituzumab (Taixinsheng ®) A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2022-04
- Registry
- NCT05508347
Age 18 years to 70 years (registered criteria)
Led by Sichuan Cancer HospitalChengdu
- RecruitingRadiotherapy Combined With Endostatin and Capecitabine for NPC
- Phase
- Phase 2
- Started
- 2022-08
- Registry
- NCT05514275
Age 18 years to 65 years (registered criteria)
Led by Zhejiang Cancer Hospital; 2 listed hospitals as study sitesHangzhou, Ningbo
- RecruitingInduction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2022-11
- Registry
- NCT05527470
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuilin, Wuzhou
- RecruitingSBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC
- Phase
- Phase 2
- Started
- 2022-09
- Registry
- NCT05652192
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingSintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
- Phase
- Not given
- Started
- 2022-07
- Registry
- NCT05707819
Age 18 years to 70 years (registered criteria)
Led by Guangxi Medical University Cancer HospitalNanning
- RecruitingConcurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma
- Phase
- N/A
- Started
- 2022-12
- Registry
- NCT05717790
Age 18 years to 70 years (registered criteria)
Led by Fourth Affiliated Hospital of Guangxi Medical University; 6 listed hospitals as study sitesGuangzhou, Guilin, Liuzhou, Wuzhou, Zhongshan
- RecruitingSurgery Plus Reduced Target Chemoradiotherapy vs Surgery Plus Reduced Dose Chemoradiotherapy for Newly Diagnosed Operable Nasopharyngeal Carcinoma.
- Phase
- N/A
- Started
- 2022-11
- Registry
- NCT06529562
Age 18 years to 70 years (registered criteria)
Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai
- RecruitingSapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2022-08
- Registry
- NCT07327216
Age 18 years to 75 years (registered criteria)
Led by Affiliated Hospital of Guangdong Medical UniversityZhanjiang
- RecruitingEffect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition
- Phase
- Phase 3
- Started
- 2021-08
- Registry
- NCT04436965
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingToripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2021-03
- Registry
- NCT04778956
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesFoshan, Guangzhou, Zhongshan
- RecruitingCamrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2021-06
- Registry
- NCT04944914
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2021-09
- Registry
- NCT05062005
Age 18 years to 65 years (registered criteria)
Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingImmune Score Based Radiomics in Nasopharyngeal Carcinoma
- Phase
- Not given
- Started
- 2021-11
- Registry
- NCT05126160
Age 18 years to 70 years (registered criteria)
Led by Zhejiang Cancer Hospital; 4 listed hospitals as study sitesHangzhou, Ningbo, Wenzhou, Wuhan
- RecruitingA Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
- Phase
- Phase 1
- Started
- 2021-11
- Registry
- NCT05194982
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Chongqing, Guangzhou, Wuhan
- RecruitingPD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
- Phase
- Phase 3
- Started
- 2020-03
- Registry
- NCT03907826
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 10 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanning, Shanghai, Wuhan, Xi'an, Xiamen
- RecruitingScreening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City
- Phase
- Not given
- Started
- 2020-04
- Registry
- NCT04085900
Age 30 years to 69 years (registered criteria)
Led by Zhongshan City People's Hospital; 1 listed hospital as study siteWuzhou, Zhongshan
- RecruitingToripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2020-06
- Registry
- NCT04376866
Age 18 years to 65 years (registered criteria)
Led by Guangxi Medical University Cancer HospitalNanning
- RecruitingPlasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma
- Phase
- N/A
- Started
- 2020-06
- Registry
- NCT04425265
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Zhuhai
- RecruitingNedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2020-08
- Registry
- NCT04437329
Age 18 years to 65 years (registered criteria)
Led by Affiliated Cancer Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingReduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2020-08
- Registry
- NCT04448522
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 3 listed hospitals as study sitesGuangzhou, Shaoguan, Wuzhou, Zhongshan
- RecruitingToripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2020-07
- Registry
- NCT04453813
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Shaoguan, Wuzhou, Zhongshan, Zhuhai
- RecruitingConcurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2020-09
- Registry
- NCT04453826
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Shaoguan, Wuzhou, Zhongshan, Zhuhai
- RecruitingDetecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC
- Phase
- Not given
- Started
- 2020-04
- Registry
- NCT04544969
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingTo Develop and Validate a Nasoendoscopic Intelligent Diagnostic System for Nasopharyngeal Carcinoma
- Phase
- Not given
- Started
- 2020-06
- Registry
- NCT04547673
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Sun Yat-sen University; 1 listed hospital as study siteGuangzhou
- RecruitingCisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2018-01
- Registry
- NCT03919552
Age 18 years to 64 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingEndoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients
- Phase
- N/A
- Started
- 2017-10
- Registry
- NCT03353467
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFoshan, Guangzhou, Nanning, Zhongshan
- Not yet recruitingIvonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07064902
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 2 listed hospitals as study sitesGuangzhou, Guilin, Xiamen
- Not yet recruitingRisk-Adapted Omission of Level Va Irradiation in Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2026-01
- Registry
- NCT07268690
Age 18 years to 70 years (registered criteria)
Led by Fujian Cancer HospitalFuzhou
- Not yet recruitingBecotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07303283
Age 18 years to 65 years (registered criteria)
Led by First Affiliated Hospital of Guangxi Medical UniversityNanning
- Not yet recruitingScipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2026-02
- Registry
- NCT07388758
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingGAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07540390
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingRadscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07756190
Age 18 years to 80 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingImpacted Tooth Management and Osteoradionecrosis Risk in NPC
- Phase
- N/A
- Started
- 2026-08
- Registry
- NCT07764887
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Guangxi Medical University; 6 listed hospitals as study sitesGuilin, Liuzhou, Nanning, Wuzhou, Zhongshan
- Not yet recruitingA Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02)
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07783321
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- Not yet recruitingPlatinum-Free Regimen in Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07794488
Age 18 years to 70 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- Not yet recruitingA Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07797881
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- Not yet recruitingA Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2026-09
- Registry
- NCT07818486
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChongqing, Guangzhou
- Not yet recruitingLocal Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2026-10
- Registry
- NCT07824856
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingBecotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2026-11
- Registry
- NCT07902713
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingDevelopment and Validation of a Biopsy Decision Model for Nasopharyngeal Carcinoma Based on Serological Markers and Endoscopic Features
- Phase
- Not given
- Started
- 2026-11
- Registry
- NCT07918755
Age 18 years to Not stated (registered criteria)
Led by Zhongshan City People's Hospital; 1 listed hospital as study siteNanning, Zhongshan
- Not yet recruitingProspective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal Carcinoma
- Phase
- Not given
- Started
- 2025-12
- Registry
- NCT05912582
Age 18 years to 80 years (registered criteria)
Led by Jiangsu Cancer HospitalNanjing
- Not yet recruitingGP Combined with Toripalimab Versus GP Induction Chemotherapy for Advanced Childhood Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT06605131
Age 6 years to 18 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingPD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2025-05
- Registry
- NCT06900218
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingA Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma
- Phase
- N/A
- Started
- 2025-07
- Registry
- NCT07062484
Age 18 years to Not stated (registered criteria)
Led by Sichuan Cancer HospitalChengdu
- Not yet recruitingShrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity
- Phase
- Phase 3
- Started
- 2025-08
- Registry
- NCT07072000
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFoshan, Guangzhou, Liuzhou, Wuzhou, Zhanjiang
- Not yet recruitingInduction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC
- Phase
- Phase 3
- Started
- 2024-01
- Registry
- NCT06095167
Age 18 years to 70 years (registered criteria)
Led by Fujian Cancer HospitalFuzhou
- Not yet recruitingKSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical Trial
- Phase
- Early phase 1
- Started
- 2024-05
- Registry
- NCT06370026
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingNeoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06680115
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Guangxi Medical UniversityNanning
- Not yet recruitingSintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPC
- Phase
- Phase 2
- Started
- 2024-12
- Registry
- NCT06752382
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- Not yet recruitingA Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC
- Phase
- Phase 3
- Started
- 2023-04
- Registry
- NCT05780294
Age 18 years to 60 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingUmbrella Biomarker-Guided Therapy in NPC
- Phase
- Phase 2
- Started
- 2022-06
- Registry
- NCT04605562
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingA Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy
- Phase
- N/A
- Started
- 2022-11
- Registry
- NCT05622474
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingEarly Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT
- Phase
- Phase 3
- Started
- 2021-03
- Registry
- NCT04215510
Age 18 years to 70 years (registered criteria)
Led by Eye & ENT Hospital of Fudan University; 3 listed hospitals as study sitesFuzhou, Nanchang, Shanghai
- Not yet recruitingAn Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC
- Phase
- Phase 2/Phase 3
- Started
- 2021-07
- Registry
- NCT04890522
Age 18 years to 60 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Enrolling by invitationPrognostic Value of TIL in Nasopharyngeal Carcinoma
- Phase
- Not given
- Started
- 2025-01
- Registry
- NCT06763640
Age 18 years to 70 years (registered criteria)
Led by Jiangxi Cancer HospitalNanchang
- Enrolling by invitationIMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06688175
Age 65 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Before contacting a hospital
The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.
- How to startTalk with the treating doctor, prepare the records hospitals ask for, then write to two or three hospitals.
- Questions to check before asking about a trialWhat the registered criteria usually ask about, and what to ask the study team.
- Common questionsInternational patients, costs, trials and visas.
National guideline (China)
- Standards for 12 childhood blood diseases and cancers (2021 edition)National Health Commission 国卫办医函〔2021〕249号, 2021-05-13; children
Written for doctors, in Chinese. We link to the official notice only and do not summarise it; it is not medical advice.
Where these numbers come from
Papers
2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search
Trials
ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 8 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.